iBio, Inc. (NYSE AMERICAN:IBIO), a biologics contract manufacturing organization and biotechnology company, announced that immunization studies for its SARS-CoV-2 Virus-Like Particle program (“IBIO-200”) are proceeding at Texas A&M University System laboratories.
The work is being performed as part of the Master Joint Development Agreement established between iBio and TAMUS in 2016. iBio created its proprietary VLP candidates in a few weeks using its FastPharming System™.
The company’s researchers then deployed this plant-based expression platform’s rapid production capabilities to deliver VLPs suitable for further development just weeks after the biologics were designed.
Led by Tom Isett, Co-Chairman & Chief Executive Officer, iBio is a global leader in plant-based biologics manufacturing. Its FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of monoclonal antibodies, vaccines, bioinks and other proteins. The company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services via its 130,000 square foot facility in Bryan, Texas.
Originally built in 2010 with funding from the U.S. Defense Advanced Research Projects Agency (DARPA), iBio’s FastPharming Facility was part of the “Blue Angel” initiative to establish factories capable of rapid delivery of medical countermeasures in response to a disease pandemic. Its FastGlycaneering Development Service™ includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, the company is developing proprietary products which include IBIO-100 for the treatment of fibrotic diseases and IBIO-200, a COVID-19 vaccine.